Redeye comments on Faron’s announcement of a planned fully pre-emptive rights issue of approximately EUR40m, aimed at funding the next phase of clinical development for bexmarilimab. We view the financing as a necessary step to advance the FDA-aligned phase II/III registrational program in frontline high-risk MDS and to support the company’s broader strategy, while recognizing that the equity raise will be noticeably dilutive.
